在移植肾的转移性去势抗原阳性前列腺癌中，对全剂量177Lu-PSMA-617放射性核素治疗的卓越反应：迈向前沿。
Excellent Response to Full-Dose 177Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney: A Step Ahead.
发表日期：2023 Aug 03
作者：
Raza Abbas Mahdi, Piyush Aggarwal, Suraj Kumar, Ashwani Sood, Davinder Paul, Bhagwant Rai Mittal
来源：
CLINICAL NUCLEAR MEDICINE
摘要：
在转移性去势抗衰老前列腺癌（mCRPC）患者中，177Lu-PSMA放射配体治疗（RLT）显示出非常令人鼓舞的结果，并且副作用可接受。RLT的副作用主要限于唾液腺和肾脏。然而，关于mCRPC转移性肾移植患者的RLT的可用数据不足。在这里，我们报告了一例68岁的mCRPC患者，患者曾有肾脏移植史，接受了4个疗程的177Lu-PSMA-617 RLT（每疗程约7.4 GBq）。治疗后血清肌酐和肾小球滤过率保持稳定，同时观察到出色的疗效和症状改善，从而证明了在肾脏移植患者中177Lu-PSMA全剂量的安全性。
版权所有 © 2023 Wolters Kluwer Health，Inc. 保留所有权利。
177Lu-PSMA radioligand therapy (RLT) has shown very encouraging results in metastatic castrate-resistant prostate cancer (mCRPC) patients with acceptable adverse events. The adverse events of RLT are mainly limited to salivary glands and kidneys. However, there is dearth of available data of RLT in transplanted kidney patients with mCRPC. Here is a case of 68-year-old mCRPC patient with history of renal transplant who underwent 4 cycles of 177Lu-PSMA-617 RLT (~7.4 GBq/cycle). Posttherapy serum creatinine and glomerular filtration rate remained stable along with excellent response and symptomatic improvement, thus demonstrating the safety of full dose of 177Lu-PSMA in renal transplant patients.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.